Antibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic Lung Cancer Trial

A closely watched Phase 3 clinical trial has delivered a sobering verdict on one of the most anticipated treatment strategies in lung cancer medicine. Sacituzumab govitecan, an antibody-drug conjugate that has shown promise in several tumor types, failed to demonstrate a statistically significant improvement in progression-free survival when combined with the immunotherapy pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express high levels of the PD-L1 protein. The primary results from the EVOKE-03/KEYNOTE-D46 trial were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer, held in Seoul, Republic of Korea, where researchers and clinicians gathered to examine whether the combination could displace pembrolizumab monotherapy as the standard of care for this patient population.

The trial enrolled 620 patients with previously untreated metastatic non-small cell lung cancer, each confirmed to have a PD-L1 tumor proportion score of at least 50 percent, a threshold that generally predicts strong responsiveness to immune checkpoint inhibitors. Patients with EGFR, ALK or ROS1 alterations were excluded, since those molecular subgroups are typically managed with targeted therapies rather than immunotherapy alone. Participants were randomized to receive either the investigational combination or pembrolizumab by itself. In the experimental arm, sacituzumab govitecan was administered at a dose of 10 mg/kg intravenously on days 1 and 8 of each cycle, alongside pembrolizumab at 200 mg on day 1 of every 21-day cycle. The study was open-label, and its dual primary endpoints were progression-free survival as assessed by blinded independent central review and overall survival.

The efficacy data revealed a pattern that has become familiar in oncology trials that miss their primary goals: encouraging numerical trends that ultimately fail the test of statistical rigor. Median progression-free survival by blinded independent central review was 11.8 months for patients receiving the combination, compared with 7.7 months for those receiving pembrolizumab alone, corresponding to a hazard ratio of 0.81 with a 95 percent confidence interval of 0.66 to 1.00 and a P value of 0.0252. Although patients on the combination lived a median of roughly four months longer without their disease progressing, the result did not cross the prespecified threshold for statistical significance that the trial design demanded.

The interim overall survival analysis was even less encouraging. Median overall survival was 21.5 months in the sacituzumab govitecan plus pembrolizumab arm versus 22.8 months with pembrolizumab alone, yielding a hazard ratio of 1.07 with a 95 percent confidence interval of 0.85 to 1.35 and a P value of 0.7155. In other words, the addition of the antibody-drug conjugate produced no survival advantage at this stage of analysis, and the point estimate actually leaned slightly in favor of monotherapy. For a field in which overall survival remains the ultimate benchmark, that finding will weigh heavily on any decision about whether the combination deserves a place in clinical practice.

Secondary measures of tumor response told a somewhat more favorable story. The confirmed objective response rate was 55.6 percent for the combination compared with 43.7 percent for pembrolizumab alone, meaning a substantially larger share of patients experienced meaningful tumor shrinkage when the antibody-drug conjugate was added. The disease control rate, reported in the study table, was 83.3 percent versus 73.1 percent, respectively. Yet the duration of those responses was nearly identical between the arms, with a median duration of response of 21.4 months for the combination and 21.3 months for pembrolizumab alone. The pattern suggests that while the combination could induce responses in more patients, it did not make the responses that occurred last any longer.

Safety findings added another layer of complexity to the interpretation. Treatment-related adverse events occurred in 93.2 percent of patients receiving the combination compared with 65.4 percent of those on pembrolizumab alone. More strikingly, grade 3 or higher treatment-related adverse events affected 55.7 percent of patients in the combination arm versus 16.5 percent in the monotherapy arm, a more than threefold increase in severe toxicity. The most common treatment-related adverse events in the combination arm included anemia, alopecia, neutropenia, diarrhea and nausea, a profile consistent with the known toxicity signature of sacituzumab govitecan. Investigators reported that the safety profile was consistent with the known profiles of the individual agents, with no new or additional toxicities observed when the two drugs were given together.

Giannis Mountzios, M.D., of the Henry Dunant Hospital Center in Athens, Greece, who presented the findings, acknowledged the tension embedded in the data. While the combination of sacituzumab govitecan and pembrolizumab produced a numerically longer progression-free survival and a higher response rate, he noted, EVOKE-03/KEYNOTE-D46 did not meet statistical significance for its primary progression-free survival endpoint, and overall survival was not significantly improved at this interim analysis. He emphasized that these findings provide important information as the field continues to evaluate treatment strategies for patients with PD-L1-high metastatic non-small cell lung cancer, framing the negative result as a contribution to knowledge rather than simply a failed experiment.

The scientific rationale behind the trial was compelling enough to justify a large Phase 3 investment. Sacituzumab govitecan links a topoisomerase I inhibitor payload to an antibody targeting TROP-2, a protein widely expressed on many epithelial cancers, including a substantial proportion of non-small cell lung tumors. The drug has already secured regulatory approvals in previously treated metastatic settings, and combining antibody-drug conjugates with immune checkpoint inhibitors has become one of the most active areas of clinical research, based on the hypothesis that chemotherapy payload-induced tumor cell death can release antigens and render tumors more visible to the immune system. Pembrolizumab, an anti-PD-1 antibody, is the established first-line standard for metastatic non-small cell lung cancer with PD-L1 tumor proportion scores of 50 percent or greater when no targetable alterations are present.

Dr. Mountzios concluded that, despite a numerical improvement in progression-free survival and a higher response rate, sacituzumab govitecan plus pembrolizumab did not meet statistical significance for progression-free survival compared with pembrolizumab monotherapy in patients with untreated PD-L1-high metastatic non-small cell lung cancer, and that overall survival also did not meet statistical significance at the interim analysis. The results leave pembrolizumab monotherapy in its longstanding position as the reference standard for this population, while raising difficult questions about whether the modest numerical gains in progression-free survival justify the substantially higher toxicity burden and the absence of any demonstrated survival benefit. For now, the trial stands as a reminder that in modern oncology, promising biology and early signals do not guarantee success when subjected to the discipline of a randomized Phase 3 test.

The International Association for the Study of Lung Cancer, founded in 1974, is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies, with a membership of more than 10,000 lung cancer specialists across all disciplines in over 100 countries. The association publishes the Journal of Thoracic Oncology and convenes the World Conference on Lung Cancer, the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, which attracts nearly 7,000 researchers, physicians and specialists from more than 100 countries each year. The conference serves as the venue where pivotal trial results such as EVOKE-03/KEYNOTE-D46 are first unveiled, shaping treatment guidelines and research agendas worldwide. As the oncology community digests these findings, attention will turn to whether further analyses, biomarker-driven subgroup explorations or alternative combination strategies can eventually translate the promise of antibody-drug conjugates into durable first-line benefits for patients with advanced lung cancer.

Subject of Research: Phase 3 testing of sacituzumab govitecan plus pembrolizumab versus pembrolizumab monotherapy as first-line treatment for PD-L1-high metastatic non-small cell lung cancer

Article Title: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

Article References: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: sacituzumab govitecan, pembrolizumab, non-small cell lung cancer, PD-L1, EVOKE-03, KEYNOTE-D46, antibody-drug conjugate, immunotherapy, progression-free survival, overall survival, Phase 3 trial, IASLC